文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

COVID-19 疫苗：免疫激活模式和未来挑战。

COVID-19 vaccines: modes of immune activation and future challenges.

机构信息

Department of Immunology and Microbiology, Scripps Research institute, La Jolla, CA, USA.

Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.

出版信息

Nat Rev Immunol. 2021 Apr;21(4):195-197. doi: 10.1038/s41577-021-00526-x.

DOI:10.1038/s41577-021-00526-x
PMID:33674759
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7934118/
Abstract

The new vaccines against SARS-CoV-2 are novel in terms of specificity, their wide dissemination across the global population and the inclusion of newly licensed mRNA platforms. We discuss here how the approved vaccines trigger innate immunity to promote durable immunological memory and consider the future implications of protecting populations with these vaccines.

摘要

新型的 SARS-CoV-2 疫苗在特异性、在全球人群中的广泛传播以及新批准的 mRNA 平台的应用方面具有创新性。我们在这里讨论了这些批准的疫苗如何引发先天免疫以促进持久的免疫记忆，并考虑了用这些疫苗保护人群的未来意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd37/7934118/cabfdcdf4556/41577_2021_526_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd37/7934118/cabfdcdf4556/41577_2021_526_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd37/7934118/cabfdcdf4556/41577_2021_526_Fig1_HTML.jpg

相似文献

[1]
COVID-19 vaccines: modes of immune activation and future challenges.

Nat Rev Immunol. 2021-4

[2]
Mixing vaccines may boost immune responses.

Science. 2021-6-11

[3]
Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic.

J Immunother Cancer. 2021-3

[4]
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.

EBioMedicine. 2022-1

[5]
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.

EBioMedicine. 2021-11

[6]
Covid-19 vaccines: delivering protective immunity.

BMJ. 2020-12-17

[7]
Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.

Nature. 2021-12

[8]
[Vaccination--new facts from basic research].

MMW Fortschr Med. 2010-7-1

[9]
Newborns' passive humoral SARS-CoV-2 immunity following heterologous vaccination of the mother during pregnancy.

Am J Obstet Gynecol. 2022-2

[10]
Fast Development of High-Quality Vaccines in a Pandemic.

Chest. 2021-7

引用本文的文献

[1]
Correlation between the immune response to COVID-19 vaccines and the constitutions of traditional Chinese medicine.

Hum Vaccin Immunother. 2025-12

[2]
Cascade amplification of therapeutic payloads for cancer immunotherapy.

Commun Biol. 2025-8-25

[3]
Retinal Vascular Occlusion Following COVID-19 Vaccination: A Comprehensive Review of Observational Study and Pathophysiological Mechanisms.

Vaccines (Basel). 2025-7-7

[4]
COVID-19-Omics Report: From Individual Omics Approaches to Precision Medicine.

Reports (MDPI). 2023-9-22

[5]
Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study.

Cancers (Basel). 2025-6-11

[6]
Impact of mRNA COVID-19 vaccination on hematological parameters in patients maintained on clozapine: A retrospective study from Qatar.

Explor Res Clin Soc Pharm. 2025-5-18

[7]
Inhaled non-viral delivery systems for RNA therapeutics.

Acta Pharm Sin B. 2025-5

[8]
Herpetic Eye Disease During the COVID-19 Pandemic at an Urban Hospital System.

Ocul Immunol Inflamm. 2025-5-23

[9]
Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster.

Front Immunol. 2025-5-8

[10]
Systemic autoinflammatory disease following COVID-19 mRNA vaccine: a severe and rare clinical presentation.

Intern Emerg Med. 2025-5-15

本文引用的文献

[1]
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.

Lancet. 2021-2-20

[2]
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

N Engl J Med. 2021-2-4

[3]
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Lancet. 2021-1-9

[4]
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

N Engl J Med. 2020-12-31

[5]
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

N Engl J Med. 2021-1-7

[6]
Anti-viral protective capacity of tissue resident memory T cells.

Curr Opin Virol. 2021-2

[7]
Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines.

Vaccines (Basel). 2020-10-1

[8]
COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses.

Nature. 2020-9-30

[9]
Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity.

Cell. 2018-10-25

[10]
mRNA vaccines - a new era in vaccinology.

Nat Rev Drug Discov. 2018-1-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索